Andrew J. Roth

Articles

Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures

May 4th 2015

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.

Oncology Nurses Poised to Make a Difference in Managing “Silent” Portal Vein Thrombosis

April 28th 2015

Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.

CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL

April 24th 2015

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Challenges, Need for New Therapies Remain in HCC

April 6th 2015

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial

March 25th 2015

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy

March 20th 2015

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

Expert Discusses Frontline Bortezomib in MCL

March 18th 2015

To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.

FDA Accepts NDA for New Formulation of Melphalan for Myeloma

March 11th 2015

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).

Antonarakis Discusses AR-V7 and Response to Taxanes in mCRPC

March 4th 2015

Emmanuel S. Antonarakis, MBBCh, discusses research examining AR-V7 as a biomarker for chemotherapy efficacy in advanced prostate cancer.

FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma

March 2nd 2015

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

Sorafenib, Sunitinib Fail in Phase III Adjuvant RCC Trial

February 23rd 2015

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Sequencing Therapies in Follicular Lymphoma Requires Multifaceted Approach

February 20th 2015

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Matulonis Discusses Integrating Olaparib Into Clinical Practice

February 16th 2015

To gain insight into the integration of olaparib into clinical practice, OncLive interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.

First Oral Proteasome Inhibitor Meets PFS Endpoint in Phase III Myeloma Trial

February 11th 2015

The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.

Dabrafenib/Trametinib Combo Continues to Show Benefit

February 6th 2015

The risk of death was significantly reduced for patients with BRAFV600E/K mutation-positive metastatic melanoma treated with dabrafenib (Tafinlar) and trametinib (Mekinist) compared with dabrafenib alone.

FDA Expands Approval of Ibrutinib to Waldenström’s macroglobulinemia

January 29th 2015

The FDA has expanded the approval of ibrutinib for the treatment of patients with Waldenström’s macroglobulinemia, according to a press release.

More Positive Data for BRAF/MEK Combo in Melanoma, But Debate Continues

January 29th 2015

The combination of trametinib (Mekinist) and dabrafenib (Tafinlar) improved overall survival (OS) compared with vemurafenib alone in patients with unresectable (stage IIIC) or metastatic (stage IV) BRAFV600E/K mutation-positive cutaneous melanoma.